NEWSpublisher 2007 :: AngloChinese Investments
SEARCH NEWS
date from:
date to:
company:
search for string:
NEWS SECTIONS
COMPANY GROUPS
TOP NEWS
» 23/07/2009 [Company watch]
China Aoxing Pharmaceutical Corp. Receives Renewal of GMP Certification for Capsule Dosage Form of Pharmaceutical Products
» 15/03/2010 [Industry news]
Recordati S.p.A And Lee Pharmaceutical Announce Partnership For Zanidip(R) In China
» 26/10/2009 [Finance]
China Growth to Remain Fast in Fourth Quarter, Official Says
» 17/08/2009 [Industry news]
Chindex Posts Profit on Product Sales, Health Services
» 07/05/2010 [Industry news]
Hong Kong: Recall of all products manufactured by Quality Pharmaceutical Lab Ltd
COMPANY NEWS back to previous page show list
Bayer »13/07/2009 [Industry news]
Scigen signs insulin deal with Bayer in China

Singapore-based biotechnology company, SciGen and its Polish holding company, Bioton have signed an exclusive insulin supply and distribution agreement with Bayer Schering Pharma, in China.

 
Scigen signs insulin deal with Bayer in China Singapore-based biotechnology company, SciGen and its Polish holding company, Bioton have signed an exclusive insulin supply and distribution agreement with Bayer Schering Pharma, in China. The agreement is to realize the group’s strategic goal of expansion of the insulin franchise through alliances with blue-chip pharma companies on most important global markets. With this agreement for long-term collaboration Bioton has materialized one of its strategic goals to develop its strong international position on growing insulin markets via alliances with leading pharmaceutical companies. We emphasize our position as a recognized leader in insulin production. Bayer is our partner of choice, said Mr Janusz R Guy, CEO, Bioton. Following execution of the agreement SciGen entered into a profit sharing agreement with Bioton. Under the profit sharing agreement SciGen will receive a share of the revenues from this agreement with Bayer. This new series of agreements are expected to be more beneficial for SciGen than its previous distribution agreement in China. This agreement represents a significant step for SciGen. Working with Bayer will make Scilin available to diabetes patients throughout China, a growing and increasingly important market, said Mr Adam Allerhand, Chairman, SciGen. According to current data, there is said to be approximately 40 million diabetic patients in China. Insulin is the fastest growing segment of the Chinese diabetes market in China with projected annual growth rates of more than 40 percent.

AngloChinese Investments ltd.
Home | Company news | TOP 50 | Events | About us
C&F Bright Solutions ltd.